Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929382 | 0.85 | ALDH1A1 (0.50) | MEN1KMT2ANPSR1ALDH1A1PKM | |
| SCHEMBL14034533 | 0.79 | ALDH1A1 (0.40) | MEN1KMT2ANPSR1ALDH1A1PKM | |
| SCHEMBL7241506 | 0.79 | MEN1 (0.60) | ADORA2AMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL7036441 | 0.79 | MEN1 (0.64) | ADORA2AMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL4929155 | 0.72 | ALDH1A1 (0.52) | NPSR1ALDH1A1PKMKDM4ELMNA | |
| SCHEMBL7038487 | 0.71 | ALDH1A1 (0.58) | ADORA2AMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL4924612 | 0.70 | ALDH1A1 (0.51) | MEN1KMT2ANPSR1ALDH1A1PKM | |
| SCHEMBL4930488 | 0.69 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1PKMLMNA | |
| SCHEMBL13791613 | 0.69 | ALDH1A1 (0.54) | ADORA2AKMT2ANPSR1ALDH1A1PKM | |
| SCHEMBL4937751 | 0.69 | ALDH1A1 (0.49) | KMT2ANPSR1ALDH1A1PKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| EP-1765814-A1 | CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006003096-A1 | CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | GLP1R, GIPR, GCGR | ADORA2A 822/4885MEN1 1203/4885KMT2A 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.